Phase 1 Graft vs Host Disease Clinical Trials
5 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Graft vs Host Disease
National Cancer Institute (NCI)50 enrolled2 locationsNCT05531786
Recruiting
Phase 1
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Graft vs Host DiseaseGraft-Versus-Host Disease
Washington University School of Medicine41 enrolled1 locationNCT06008808
Recruiting
Phase 1
IS-free Treg HaploHCT
Myelodysplastic SyndromesStem Cell Transplant ComplicationsGraft vs Host Disease+2 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT04678401
Recruiting
Phase 1Phase 2
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Graft vs Host Disease
Northwell Health10 enrolled1 locationNCT06681922
Recruiting
Phase 1
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
Graft vs Host Disease
Fujian Medical University17 enrolled1 locationNCT06568328